GRAIL, Inc. (GRAL)
59.13
+0.54
(+0.92%)
USD |
NASDAQ |
Jun 11, 13:26
GRAIL Revenue (Quarterly) : 40.78M for March 31, 2026
Revenue (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Revenue (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2026 | 40.78M |
| December 31, 2025 | 43.60M |
| September 30, 2025 | 36.19M |
| June 30, 2025 | 35.54M |
| March 31, 2025 | 31.84M |
| December 31, 2024 | 38.25M |
| September 30, 2024 | 28.65M |
| June 30, 2024 | 31.97M |
| Date | Value |
|---|---|
| March 31, 2024 | 26.72M |
| December 31, 2023 | 30.33M |
| September 30, 2023 | 20.72M |
| June 30, 2023 | 22.41M |
| March 31, 2023 | 19.64M |
| September 30, 2020 | 0.00 |
| September 30, 2019 | 0.00 |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Revenue (Quarterly) Benchmarks
| Apogee Therapeutics, Inc. | 0.00 |
| Evommune, Inc. | 0.00 |
| Arrowhead Pharmaceuticals, Inc. | 73.74M |
| Oncolytics Biotech, Inc. | 0.00 |
| Sangamo Therapeutics, Inc. | 1.442M |
Revenue (Quarterly) Related Metrics
| Net Income (Quarterly) | -93.19M |
| Total Expenses (Quarterly) | 133.97M |
| EPS Diluted (Quarterly) | -2.293 |
| Enterprise Value | 1.638B |
| Gross Profit Margin (Quarterly) | -37.81% |
| Profit Margin (Quarterly) | -228.5% |
| Earnings Yield | -17.55% |
| Normalized Earnings Yield | -16.62 |